Recovery from Pneumocystis carinii pneumonia in dexamethasone-treated Wistar rats (original) (raw)

Abstract

Our aim was to study histopathological changes in lung tissue at the light microscopic and ultrastructural level during recovery from immunosuppres- sion and Pneumocystis carinii pneumonia. Male Wistar rats were immunosuppressed by per oral dexamethasone for 12 weeks to induce P. carinii pneumonia, after which dexamethasone was stopped. Recovery was monitored 1, 2 and 4 weeks after cessation of the

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (35)

  1. Meuwissen JHET, Tauber I, Leeuwenberg ADEM, Beckers PJA, Sieben M. Parasitologic and serologic observations of infection with Pneumocystis in humans. J Infect Dis 1977; 136: 43-49.
  2. Pifer LL, Hughes WT, Stagno S, Woods D. Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children. Pediatrics 1978; 61: 35-41.
  3. Masur H, Lane HC, Kovacs JA, Allegra CJ, Edman JC. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med 1989; 111: 813-826.
  4. Murray JF, Felton CP, Garay SM, et al. Pulmonary com- plications of the acquired immunodeficiency syndrome. N Engl J Med 1984; 310: 1682-1688.
  5. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type-1. N Engl J Med 1990; 322: 161-165.
  6. Beck JM, Warnock ML, Curtis JL, et al. Inflammatory responses to Pneumocystis carinii in mice selectively depleted of helper T-lymphocytes. Am J Respir Cell Mol Biol 1991; 5: 186-197.
  7. Harmsen AG, Stankiewicz M. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 1990; 172: 937-945.
  8. Shellito J, Suzara W, Blumenfeld W, Beck JM, Steger HJ, Ermak TH. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T- lymphocytes. J Clin Invest 1990; 85: 1685-1693.
  9. Walzer PD, Labine M, Redington J, Cushion MT. Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumo- cystis carinii pneumonia. J Immunol 1984; 133: 2502-2508.
  10. Agostini C, Zambello R, Trentin L, et al. Prognostic significance of the evaluation of bronchoalveolar lavage cell populations in patients with HIV-1 infection and pul- monary involvement. Chest 1991; 100: 1601-1606.
  11. Kägi MK, Fierz W, Grob PJ, Russi EW. High propor- tion of gamma-delta T-cell receptor positive T-cells in bronchoalveolar lavage and peripheral blood of HIV- infected patients with Pneumocystis carinii pneumonias. Respiration 1993; 60: 170-177.
  12. Pesanti E. Phospholipid profile of Pneumocystis carinii and its interaction with alveolar type II epithelial cells. Infect Immun 1987; 55: 736-741.
  13. Smulian AG, Walzer PD. The biology of Pneumocystis carinii. Crit Rev Microbiol 1992; 18: 191-216.
  14. Tamburrini E, Deluca A, Ventura G, Maiuro G, Siracusano A. Pneumocystis carinii stimulates in vitro production of tumor necrosis factor-alpha by human macrophages. Med Microbiol Immunol 1991; 180: 15-20.
  15. Corsini E, Dykstra C, Craig WA, Tidwell RR, Rosenthal GJ. Pneumocystis carinii induction of tumor necrosis factor-α by alveolar macrophages: modulation by pen- tamidine isethionate. Immunol Lett 1992; 34: 303-308.
  16. Huang ZB, Eden E. Effect of corticosteroids on IL-1- beta and Tnf-alpha release by alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumo- nia. Chest 1993; 104: 751-755.
  17. Quay J, Rosenthal G, Becker S. Effect of pentamidine on cytokine (IL-1-beta, TNF-alpha, IL-6) production by human alveolar macrophages in vitro. Exp Lung Res 1993; 19: 429-443.
  18. Sukura A, Soveri T, Lindberg L-A. Superiority of methyl- prednisolone over dexamethasone for induction of Pneumocystis carinii infection in rats. J Clin Microbiol 1991; 29: 2331-2332.
  19. Gill VJ, Nelson NA, Stock F, Evans G. Optimal use of the cytocentrifuge for recovery and diagnosis of Pneumo- cystis carinii in bronchoalveolar lavage and sputum spec- imens. J Clin Microbiol 1988; 26: 1641-1644.
  20. Barcalay AN. The localization of populations of lympho- cytes defined by monoclonal antibodies in rat lymphoid tissues. Immunology 1981; 42: 593-600.
  21. Sukura A, Ukkola T, Linder E, Lindberg L-A. Ultrastruc- tural localization of monoclonal antibodies against Pneumo- cystis carinii: differentiation between developmental stage and host origin. APMIS (in press).
  22. Maury CP, Teppo AM. Raised serum levels of cachetin/ tumor necrosis factor-alpha in renal allograft rejection. J Exp Med 1987; 166: 1132-1137.
  23. Siegel J, ed. Statistix, version 4, users's manual. St Paul, MN, USA, Analytical Software, 1992.
  24. Freund RJ, Littell RC. SAS for linear models. Cary, NC, USA, SAS Institute Inc., 1981.
  25. Hughes WT. Foreword. In: Hopkin JM, ed. Pneumocystis carinii, New York, Oxford Univesity Press, 1991.
  26. Kovacs JA, Masur H. Prophylaxis of Pneumocystis carinii pneumonia: an update. J Infect Dis 1989; 160: 882- 886.
  27. Kovacs JA, Masur H. Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immuno- deficiency virus. Clin Infect Dis 1992; 14: 1005-1009.
  28. Beck JM, Liggitt HD, Brunette EN, Fuchs HJ, Shellito JE, Debs RJ. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 1991; 59: 3859- 3862.
  29. Pesanti EL. Interaction of cytokines and alveolar cells with Pneumocystis carinii in vitro. J Infect Dis 1991; 163: 611-618.
  30. Sherman MP, Loro ML, Wong VZ, Tashkin DP. Cytokine- and Pneumocystis carinii-induced L-arginine oxidation by murine and human pulmonary alveolar macrophages. Protozool 1991; 38: 234s-236s.
  31. Chen W, Havell EA, Harmsen AG. Importance of endo- genus tumor necrosis factor-alpha and gamma interfer- on in host resistance against Pneumocystis carinii infection. Infect Immun 1992; 60: 1279-1284.
  32. Gigliotti F, Haidaris PJ, Haidaris CG, Wright TW, Vandermeid KR. Further evidence of host species spe- cific variation in antigens of Pneumocystis carinii using the polymerase chain reaction. J Infect Dis 1993; 168: 191-194.
  33. Sinclair K, Wakefield AE, Banerji S, Hopkin JM. Pneumo- cystis carinii organisms derived from rat and human hosts are genetically distinct. Mol Biochem Parasitol 1991; 45: 183-184.
  34. Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE. The role of CD4+ and CD8+ T-cells in the protective inflammatory response to a pulmonary cryp- tococcal infection. J Leukoc Biol 1994; 55: 35-42.
  35. Shear HL, Valladares G, Narachi MA. Enhanced treat- ment of Pneumocystis carinii pneumonia in rats with interferon-gamma and reduced doses of trimethoprim sul- famethoxazole. J Acquir Immune Defic Syndr 1990; 3: 943-948.